Key result
In an in vitro solid tumor model, micellar doxorubicin (NK911) distributed throughout tumor spheroids including the center, whereas liposomal doxorubicin (Doxil) distributed only to the surface.
Population
In vitro solid tumor model using spheroids formed from human colonic cancer lines and a human stomach cancer…
Comparison
Micellar doxorubicin (NK911) vs Liposomal doxorubicin (Doxil)
Design
Preclinical
Authors
Loading...
May warrant testing micellar doxorubicin for deeper tumor access; leaves open translation from spheroid models to patients.
Micellar doxorubicin (NK911) penetrates solid tumor spheroids more effectively than liposomal doxorubicin (Doxil), despite being less stable in saline, suggesting different optimal clinical applications based on tumor vasculature.
Tsukioka et al. (2002) studied Solid tumor model (in vitro). Micellar doxorubicin (NK911) vs. Liposomal doxorubicin (Doxil) was evaluated on Stability and biological behavior (drug distribution in spheroids). In an in vitro solid tumor model, micellar doxorubicin (NK911) distributed throughout tumor spheroids including the center, whereas liposomal doxorubicin (Doxil) distributed only to the surface.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: